261 related articles for article (PubMed ID: 7851494)
21. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
Alcántara AI; Morales M; Delgado E; López-Delgado MI; Clemente F; Luque MA; Malaisse WJ; Valverde I; Villanueva-Peñacarrillo ML
Arch Biochem Biophys; 1997 May; 341(1):1-7. PubMed ID: 9143346
[TBL] [Abstract][Full Text] [Related]
22. Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig.
Singh G; Eng J; Raufman JP
Regul Pept; 1994 Aug; 53(1):47-59. PubMed ID: 7800858
[TBL] [Abstract][Full Text] [Related]
23. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG
J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947
[TBL] [Abstract][Full Text] [Related]
24. The gastric acid secretagogue gastrin-releasing peptide and the inhibitor oxyntomodulin do not exert their effect directly on the parietal cell in the rat.
Gehl J; Jeppesen JL; Poulsen SS; Holst JJ
Digestion; 1988; 40(3):144-51. PubMed ID: 3234620
[TBL] [Abstract][Full Text] [Related]
25. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues.
Pohl M; Wank SA
J Biol Chem; 1998 Apr; 273(16):9778-84. PubMed ID: 9545315
[TBL] [Abstract][Full Text] [Related]
26. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
27. Effect of substance P and neurokinin A on rat parietal cell function.
Schepp W; Schmidtler J; Tatge C; Schusdziarra V; Classen M
Am J Physiol; 1990 Oct; 259(4 Pt 1):G646-54. PubMed ID: 1699430
[TBL] [Abstract][Full Text] [Related]
28. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
29. Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.
Gong N; Fan H; Ma AN; Xiao Q; Wang YX
Neuropharmacology; 2014 Sep; 84():31-45. PubMed ID: 24747181
[TBL] [Abstract][Full Text] [Related]
30. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
31. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
Barragán JM; Rodríguez RE; Eng J; Blázquez E
Regul Pept; 1996 Nov; 67(1):63-8. PubMed ID: 8952007
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
33. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
[TBL] [Abstract][Full Text] [Related]
34. Cyclic GMP and acid production in isolated gastric cells of the rat.
Heim HK; Ruoff HJ
Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):147-54. PubMed ID: 2413374
[TBL] [Abstract][Full Text] [Related]
35. Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.
Radziszewska E; Bojanowska E
Med Sci Monit Basic Res; 2013 Jan; 19():6-11. PubMed ID: 23291632
[TBL] [Abstract][Full Text] [Related]
36. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.
Carraro-Lacroix LR; Malnic G; Girardi AC
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1647-55. PubMed ID: 19776173
[TBL] [Abstract][Full Text] [Related]
37. Effects of glucagon and histamine on human parietal cells.
Schepp W; Ruoff HJ; Dein HJ; Miederer S
Agents Actions; 1986 Apr; 18(1-2):214-8. PubMed ID: 3728203
[TBL] [Abstract][Full Text] [Related]
38. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat.
Bao W; Holt LJ; Prince RD; Jones GX; Aravindhan K; Szapacs M; Barbour AM; Jolivette LJ; Lepore JJ; Willette RN; DeAngelis E; Jucker BM
Cardiovasc Diabetol; 2013 Oct; 12():148. PubMed ID: 24125539
[TBL] [Abstract][Full Text] [Related]
39. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus.
Owji AA; Khoshdel Z; Sanea F; Panjehshahin MR; Shojaee Fard M; Smith DM; Coppock HA; Ghatei MA; Bloom SR
Brain Res; 2002 Mar; 929(1):70-5. PubMed ID: 11852032
[TBL] [Abstract][Full Text] [Related]
40. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.
Al-Sabah S; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):9-14. PubMed ID: 14965273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
